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Non-coding RNAs (ncRNAs) were at first 
thought to be a non-specific noise. The vast 
majority of them have yet to be character-
ized thoroughly, but many of these ncRNAs 
are unlikely to represent transcriptional 
noise as a significant number have been 
shown to exhibit cell type-specific expres-
sion, localization to subcellular compart-
ments, and association with human diseases 
(Wilusz et al., 2009). Although ncRNAs do 
not encode protein, this does not mean that 
such RNAs do not contain information nor 
have function. Widespread transcription of 
ncRNAs is now known to occur in all species 
and they are likely to represent a fundamen-
tal process in biological systems.
Most of the newly identified ncRNAs’ 
functions are unknown, but these tran-
scripts are increasingly recognized as regu-
lators of gene expression. They appear to 
comprise a hidden layer of internal signals 
that control various levels of gene expression 
in physiology and development, including 
chromatin architecture/epigenetic memory 
(a  process by which changes in gene expres-
sion are passed on via mitosis or meiosis 
through factors other than DNA sequence, 
e.g., involving histones and methylation 
patterns), transcription, RNA splicing, edit-
ing, translation, and turnover. RNA regula-
tory networks may determine most of our 
complex characteristics and play a signifi-
cant role in disease (Mattick and Makunin, 
2006). Indeed, examples of ncRNAs with 
specific roles in a range of developmental 
processes have been reported. The roles 
of ncRNAs are many and diverse. As they 
involve in the regulation of cellular dif-
ferentiation and proliferation, the altered 
expression of key ncRNAs may lead to cer-
tain human diseases (Irminger-Finger et al., 
2010). Precisely what ncRNAs do and how 
they work is a current hot topic in the sci-
entific and medical fields.
MicroRNA (miRNA) is one important 
subcategory of ncRNAs. Most of these 
molecules appear to regulate target gene 
expression through translation repression 
or mRNA degradation (Cho, 2007). The 
biological functions of miRNAs are yet to be 
completely revealed. Nevertheless, increas-
ing number of studies indicate that miRNAs 
are emerging as important modulators in 
cellular pathways and they play a key role 
in human diseases (Cho, 2010a). Recent 
reports reveal that miRNAs play significant 
regulatory roles in a variety of biological 
processes, including adipocyte differentia-
tion, metabolic integration, insulin resist-
ance, and appetite regulation. Investigation 
of these molecules and their genetic targets 
may potentially identify new pathways 
involved in complex metabolic disease 
processes, improving our understanding of 
metabolic disorders, and influence future 
approaches to the treatment of metabolic 
syndrome (Heneghan et al., 2010). Study of 
miRNA biogenesis and function may also 
add new tools for gene functional study and 
drug development. Indeed, the rapid dis-
covery of many miRNA targets and their 
associated pathways has contributed to the 
development of miRNA-based therapeutics 
(Cho, 2010b). Emerging evidence reveals 
the potential of miRNA studies translat-
ing from bench to bedside applications 
(Cho, 2011).
Another topic of intense research inter-
est is the small interfering RNAs (siRNAs). 
They inhibit gene expression by participat-
ing in RNA interference (RNAi). The iden-
tification of lipidoids facilitate high levels 
of specific silencing of endogenous gene 
transcripts when formulated with either 
double-stranded siRNA or single-stranded 
antisense 2′-O-methyl oligoribonucleotides 
targeting ncRNA (Akinc et al., 2008). The 
phosphate buffered saline-formulated 
locked nucleic acid-modified oligonucle-
otide and liposome-polycation-hyaluronic 
acid nanoparticle formulation modified 
with tumor-targeting single-chain antibody 
fragment enable systemic targeted delivery 
of siRNA (Elmén et al., 2008; Chen et al., 
2010). Over the past few years, a number 
of studies have revealed that siRNA is a 
potent method of gene silencing. RNAi has 
been extensively used for the fundamental 
research of therapeutics and has displayed 
great potential in clinical treatment.
The long ncRNAs (lncRNAs) are another 
important class of ncRNAs. In mammals 
and other eukaryotes, most of the genome 
is transcribed in a developmentally regu-
lated manner to produce large numbers of 
lncRNAs (Mercer et al., 2009). Emerging 
evidences suggest that lncRNAs function 
as epigenetic regulators of transcription 
in human cells. Mechanistically, these 
lncRNAs may be involved in maintaining 
balanced transcription at bidirectionally 
transcribed loci as a method to modulate 
gene expression according to the selective 
pressures placed on the cell. The loss of this 
intricate bidirectional RNA-based regula-
tory network can result in overt epigenetic 
silencing of gene expression (Morris, 2009). 
Rather than silently accumulating in the 
nucleus, many lncRNAs are now believed 
to play important roles in nuclear architec-
ture or in the regulation of gene expression 
(Chen and Carmichael, 2010).
Development of personalized medicine 
is closely linked to biomarkers (Villanueva 
et al., 2010). Since epigenetic changes often 
precede disease pathology, they may act as 
valuable diagnostic indicators for disease 
risk or prognostic indicators for disease 
progression (Kelly et al., 2010). Some 
aspects of epigenetics are strongly linked to 
ncRNAs and the role of ncRNAs as molecu-
lar biomarkers for human diseases is being 
supported by an increasing number of stud-
ies. Yet, there are many challenges that the 
researchers have to conquer before ncRNAs 
can be fully understood and utilized.
Firstly, it is a challenge to detect small 
RNAs because of their small size, lack of 
an open reading frame, and diverse nature 
(Hershberg et al., 2003). Rapid devel-
opment in high-throughput platform 
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functional interpretation in conjunction 
with clinical results may help to overcome 
this challenge (Cho, 2010c).
Although the biological importance of 
ncRNA is becoming increasingly apparent, 
regulation of ncRNA expression in human 
diseases is not fully understood. There are 
some questions to be addressed. ncRNA 
dysregulation has been linked to changes 
in epigenetic regulation, such as the meth-
ylation status of miRNA genes, which 
results in alterations in their expression 
levels. As some ncRNAs have an impor-
tant role in self-renewal and differentia-
tion of embryonic and tissue-specific stem 
cells, do they also have a regulatory role 
in cancer stem cells? Promising findings of 
a disease-associated ncRNA in one study 
is not adequate to support a solid report; 
multicenter and an independent cohort 
of studies would be needed to cross vali-
date the discovery. ncRNA studies indi-
cate their importance and potential use 
as theranostic tools, but the true clinical 
utility and the limits of their applica-
tion are yet to be established. Although 
ncRNA-based therapeutics in several 
proof-of-principle experiments have dem-
onstrated exciting effects, the developing 
progress of antisense or siRNA drugs has 
been hampered by stability, specificity, and 
delivery problems. Even though the LNA 
technology has presented a breakthrough 
in oligonucleotide carrier in recent years; 
results from clinical trials are still pend-
ing to confirm the use of this antagomir 
in respect to safety for human applica-
tion. Nevertheless, the rapid progress in 
ncRNA studies points to their tremendous 
potential in the management of human 
diseases and their potential role in future 
therapeutics (Cho, 2009).
Non-coding RNAs is a cutting-edge topic 
in the scientific and medical fields, the iden-
tification of disease-related ncRNAs and 
their state-of-the-art treatment approaches 
proceed at a fast pace. Although there are 
many challenges to be passed through, new 
forms and uses of ncRNAs will continue to 
be discovered. However, much more work 
remains to be accomplished before the 
diverse nature of these RNA molecules can 
be fully understood.
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technologies, such as single-nucleotide 
polymorphism analysis, genome-wide 
transcriptional profiling, microarray, 
BeadArray, and next generation sequenc-
ing offers the potential for revolutionary 
development in the study of ncRNAs. 
The widespread and comprehensive use 
of microarrays has enabled the identifica-
tion of a number of ncRNAs as potential 
biomarkers for a variety of human diseases 
(Cho, 2010c).
In addition, a challenge to ncRNA stud-
ies lies in the prediction of target genes. 
For example, miRNAs target mRNAs that 
contain partially complementary sites to 
the miRNA. The level of complementa-
rity is different between target site-miRNA 
pairs, and finding target genes has proved 
to be a bigger challenge than expected. 
Even after the identification of ncRNAs 
and their target genes, it is also a chal-
lenge to reveal their specific biological 
function and signaling pathways (Inui 
et al., 2010). Recent advances in bioinfor-
matics have provided new opportunity in 
the molecular analysis of various human 
diseases in an unprecedented speed. Some 
studies not only reported the identified 
ncRNA biomarkers, but also deciphered 
their target genes and the underlying 
mechanisms. The rapid discovery of many 
ncRNA targets and their relevant pathways 
has contributed to the development of 
ncRNA-based therapeutics (Cho, 2010d). 
However, the safe and effective delivery of 
RNAi therapeutics in vivo remains a sig-
nificant clinical challenge.
On the other hand, some particular 
ncRNAs can target numerous mRNAs, 
often in combination with other ncRNAs. 
Complex diseases are affected by a number 
of ncRNAs rather than a single ncRNA, 
and ncRNAs operate in highly complex 
regulatory networks (Kargul and Laurent, 
2010). It is a challenge to identify ncRNA 
synergism, determine their functions at a 
system-wide level, and investigate disease 
ncRNA features in the ncRNA–ncRNA syn-
ergistic network from a holistic view (Xu 
et al., 2011). The development of microar-
rays, RT-PCR platforms, and next genera-
tion sequencing methodologies has resulted 
in an exponential acquisition of ncRNA 
profiles. However, there is no database 
that allows for cross-platform comparison 
of existing data (Farazi et al., 2011). The 
integration of various omics data and their 
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